Immunocore (NASDAQ:IMCR) Earns "Buy" Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Immunocore (NASDAQ:IMCR - Free Report) in a research report sent to investors on Monday,Benzinga reports. They currently have a $100.00 price objective on the stock.

Several other brokerages have also issued reports on IMCR. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Immunocore in a research note on Tuesday, May 27th. They set a "buy" rating and a $65.00 target price on the stock. Needham & Company LLC reissued a "buy" rating and set a $71.00 target price on shares of Immunocore in a research report on Thursday, April 10th. Oppenheimer raised their price objective on shares of Immunocore from $85.00 to $86.00 and gave the stock an "outperform" rating in a report on Thursday, May 8th. Mizuho reduced their target price on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a research note on Monday, April 7th. Finally, JPMorgan Chase & Co. cut their price objective on shares of Immunocore from $54.00 to $50.00 and set an "overweight" rating for the company in a report on Monday, April 14th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $58.89.

Immunocore Stock Performance

NASDAQ IMCR traded down $0.01 during trading on Monday, reaching $38.64. The company's stock had a trading volume of 432,931 shares, compared to its average volume of 379,840. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03. The firm has a market capitalization of $1.94 billion, a price-to-earnings ratio of -40.67 and a beta of 0.75. Immunocore has a 12 month low of $23.15 and a 12 month high of $43.97. The firm has a 50 day moving average price of $29.56 and a 200 day moving average price of $30.00.

Immunocore (NASDAQ:IMCR - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $0.10 EPS for the quarter, beating the consensus estimate of ($0.35) by $0.45. Immunocore had a negative net margin of 15.87% and a negative return on equity of 12.84%. The company had revenue of $125.13 million during the quarter, compared to analysts' expectations of $108.82 million. During the same period in the previous year, the company earned ($0.49) EPS. The business's revenue for the quarter was up 33.6% compared to the same quarter last year. As a group, equities analysts anticipate that Immunocore will post -0.94 EPS for the current fiscal year.

Insider Activity at Immunocore

In other Immunocore news, Director Bros. Advisors Lp Baker bought 807,338 shares of the company's stock in a transaction dated Monday, March 17th. The shares were purchased at an average price of $29.72 per share, for a total transaction of $23,994,085.36. Following the acquisition, the director now owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This represents a 60.40% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. 10.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Immunocore

A number of hedge funds have recently bought and sold shares of IMCR. T. Rowe Price Investment Management Inc. increased its position in shares of Immunocore by 5.2% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 7,051,818 shares of the company's stock valued at $209,228,000 after purchasing an additional 351,610 shares during the last quarter. Primecap Management Co. CA increased its position in shares of Immunocore by 0.4% during the 1st quarter. Primecap Management Co. CA now owns 2,678,650 shares of the company's stock valued at $79,476,000 after purchasing an additional 10,100 shares during the last quarter. Baker BROS. Advisors LP increased its position in shares of Immunocore by 53.3% during the 1st quarter. Baker BROS. Advisors LP now owns 2,322,656 shares of the company's stock valued at $68,913,000 after purchasing an additional 807,338 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Immunocore by 1.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 2,187,530 shares of the company's stock valued at $64,533,000 after purchasing an additional 29,832 shares during the last quarter. Finally, Tang Capital Management LLC increased its position in shares of Immunocore by 40.7% during the 4th quarter. Tang Capital Management LLC now owns 1,555,600 shares of the company's stock valued at $45,890,000 after purchasing an additional 450,000 shares during the last quarter. Institutional investors own 84.50% of the company's stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.